Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Holdings Increased by Quantbot Technologies LP

Quantbot Technologies LP grew its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 236.6% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 18,745 shares of the company’s stock after buying an additional 13,176 shares during the quarter. Quantbot Technologies LP’s holdings in Myriad Genetics were worth $257,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Point72 Hong Kong Ltd bought a new position in Myriad Genetics during the third quarter worth $32,000. KBC Group NV lifted its position in shares of Myriad Genetics by 132.8% in the 4th quarter. KBC Group NV now owns 5,845 shares of the company’s stock worth $80,000 after buying an additional 3,334 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Myriad Genetics by 43.8% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company’s stock valued at $132,000 after buying an additional 1,471 shares during the period. Inspire Advisors LLC grew its position in shares of Myriad Genetics by 48.1% during the 4th quarter. Inspire Advisors LLC now owns 11,226 shares of the company’s stock valued at $154,000 after buying an additional 3,644 shares during the last quarter. Finally, E Fund Management Co. Ltd. bought a new position in Myriad Genetics in the fourth quarter worth about $161,000. Institutional investors and hedge funds own 99.02% of the company’s stock.

Myriad Genetics Price Performance

Shares of NASDAQ:MYGN opened at $8.88 on Friday. The stock has a market cap of $810.82 million, a price-to-earnings ratio of -6.83 and a beta of 1.79. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. Myriad Genetics, Inc. has a 12 month low of $8.70 and a 12 month high of $29.30. The stock’s 50 day moving average price is $11.76 and its 200 day moving average price is $16.50.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The firm had revenue of $210.60 million during the quarter, compared to the consensus estimate of $210.35 million. During the same period in the prior year, the firm posted ($0.12) EPS. Equities research analysts anticipate that Myriad Genetics, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on MYGN. Piper Sandler raised Myriad Genetics from a “neutral” rating to an “overweight” rating and upped their target price for the company from $11.50 to $12.50 in a report on Wednesday, March 12th. The Goldman Sachs Group lowered their price objective on Myriad Genetics from $29.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Stephens reiterated an “equal weight” rating and issued a $20.00 target price on shares of Myriad Genetics in a research note on Thursday, January 16th. StockNews.com upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research report on Tuesday, March 25th. Finally, Bank of America cut their price objective on shares of Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating on the stock in a research report on Monday, March 3rd. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $21.89.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.